Dr. Suresh Gadde
Dr. Suresh Gadde
Assistant Professor, Department of Cellular and Molecular Medicine

MSc Chemistry, University of Hyderabad, India
PhD Chemistry, Wichita State University, USA
Postdoctoral Associate, University of Miami, USA
Postdoctoral Associate, Brigham and Women’s Hospital, Harvard Medical School, USA

Roger Guindon Hall, room 4209
613-562-5800 ext. 4882


Recent publications

  • El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E, McGarry S, Liu D,  Zheng P, Lee S-H, Cui J, Ekker M, Cote M, Alain T, Li X, Costa VM, Wang L@Gadde S@. A triple-drug nanotherapy to target breast cancer cells, cancer stem cells and tumor vasculature. Cell Death & Disease 2020 (Accepted). @Co-corresponding authors
  • Sulaiman A, McGarry S, El-Sahli S, Li L, Chambers J, Phan A, Al-Kadi E, Kahil Z, Farah E, Ji G, Lee S-H, Inampudi KK, Alain T, Li X, Liu S, Han X, Zheng P, Liu Z, Gadde S@, Wang L@. Nanoparticles loaded with Wnt and YAP/mevalonate inhibitors in combination with paclitaxel stop the growth of TNBC patient-derived xenografts and diminish tumorigenesis. Advanced Therapeutics 2020@ Co-corresponding authors
  • Syed AM, MacMillan P, Ngai J, Wilhelm S, Sindhwani S, Kingston BR, Wu JLY, Llano-Suarez P, Lin ZP, Ouyang B, Kahiel Z, Gadde S, Chan WCW. Liposome imaging in optically cleared tissues. Nano Letters 2020, 2, 1362
  • Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, MacMillan P, Zhang Y, Rajesh NU, Hoang T, Wu JL, Wilhelm S, Zilman A, Gadde S, Sulaiman A, Ouyang B, Lin Z, Wang L, Egeblad M, Chan WCW. How do nanoparticles enter solid tumours? Nature Materials 2020, 1-10
  • Smith TKT, Kahil Z, Leblond N, Ghorbani P, Farah E, Al-Awosi R, Cote M, Gadde S@, Fullerton M @. Characterization of LXR-activating nanoparticle formulations in primary mouse macrophages. Molecules 2019, 24, 3751. @ Co-corresponding authors
  • Nguyen M, Wyatt H, Susser L, Geoffrion M, Rasheed A, Duchez A-C, Cottee ML,  Afolayan E, Farah E, Kahil Z, Cote M, Gadde S@, Rayner K@Delivery of microRNAs by chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS Nano 2019, 13, 6491@ Co-corresponding authors
  • Sulaiman A, McGarry S, El-Sahli S, Li L, Chambers J, Phan A, Côté M, Cron GO, Alain T, Le Y, Lee S-H, Liu S, Figeys D, Gadde S@, Wang L@. Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy. Molecular Cancer Therapeutics 2019, 18, 1755. @Co-corresponding authors

Research interests

  • Translational nanomedicines
  • Targeted nanotherapeutics
  • Biomaterials
  • Nano-bio interactions
  • Imaging
  • Cancer
  • Atherosclerosis
  • Inflammation